




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61M 37/00	A1	(11) International Publication Number: WO 98/08565 (43) International Publication Date: 5 March 1998 (05.03.98)
<p>(21) International Application Number: PCT/US97/11051</p> <p>(22) International Filing Date: 26 June 1997 (26.06.97)</p> <p>(30) Priority Data: 08/705,334 29 August 1996 (29.08.96) US</p> <p>(71) Applicant: LIGHT SCIENCES LIMITED PARTNERSHIP [US/US]; 1065 - 12th Avenue N.W. #E5, Issaquah, WA 98027 (US).</p> <p>(72) Inventor: CHEN, James, C.; 2011 - 87th Place N.E., Bellevue, WA 98004 (US).</p> <p>(74) Agent: ANDERSON, Ronald, M.; Law Offices of Ronald M. Anderson, Suite 1710, 500 - 108th Avenue N.E., Bellevue, WA 98004 (US).</p>	<p>(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published With international search report. With amended claims.</p>	

(54) Title: IMPROVED TRANSCUTANEOUS ELECTROMAGNETIC ENERGY TRANSFER



(57) Abstract

A method and apparatus for enhancing transcutaneous energy transfer to provide power to a medical device that is disposed within the body of a patient. A magnetic field is created by an external transmitting coil (200), which induces an electrical current in a receiving coil (300) that has been placed under the patient's skin (100). The flux path magnetic permeability between the receiving and transmitting coils is enhanced by the implantation of particles (120) into dermis (104) within the skin at that site. The particles, which comprise soft iron or other material having a characteristic high magnetic permeability, are preferably implanted using either a hypodermic needle (150) or a medical air injection device (160). A biocompatible material such as Teflon™ is applied as a coating (123) to the particles. To implant the particles, they are preferably first suspended in a liquid, forming a mixture that is readily delivered to the desired location. The particles are dispersed in a deposit below the epidermis, so that the deposit is between pole faces of the transmitting and the receiving coils. The efficiency of transcutaneous power transfer increases because the magnetic flux density coupling the transmitting and receiving coils is improved by the particles.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

IMPROVED TRANSCUTANEOUS ELECTROMAGNETIC ENERGY TRANSFER

Field of the Invention

This invention generally relates to the transfer of electromagnetic energy
5 between a source coil and a receiver coil, and more specifically, to a method and
system for improving the efficiency with which electromagnetic power is
transcutaneously transferred to energize a medical device implanted within a
patient's body.

Background of the Invention

10 Various types of medical devices such as cochlear implants, artificial
hearts, and neural stimulators have been developed that are designed to be
surgically inserted within a patient's body to carry out a medically related function
for an extended period of time. Although a power lead connected to the implanted
device and extending outside the patient's body can be used to supply electrical
15 power required to energize the device, any lead that passes through the skin
increases the risk of infection if left in place for more than a few days. Thus,
power can be supplied to an implanted medical device from an internal battery
pack to avoid this problem. However, any battery used for extended periods of
time will eventually need to either be recharged or replaced. Replacing an
20 internally implanted battery subjects the patient to further invasive surgery and is
thus not desirable.

An alternative solution to this problem provides for recharging the battery
by transcutaneously coupling power from an external source to an implanted
receiver that is connected to the battery. Although power can be coupled from an
25 external source at radio frequencies using matching antennas, it is generally more
efficient to employ an external transmitter coil and an internal receiving coil that
are inductively electromagnetically coupled to transfer power at lower
frequencies. In this approach, the external transmitter coil is energized with

alternating current (AC), producing a varying magnetic flux that passes through the patient's skin and excites a corresponding AC current in the internal receiving coil. The current in the receiving coil is then typically rectified and filtered for use in charging a battery pack that provides power to the implanted device, but
5 may also be directly applied for powering the implanted device. It should be noted that the receiving coil and any related electronic circuitry may be located at a different point in the patient's body from that at which the implanted device is disposed.

The efficiency with which electromagnetic power is transcutaneously
10 transferred between two coils is a function of the distance between the coils, the design of the coils, including the type of core used for each, the size of the core of each coil, the number of turns of electrical conductor used for each coil, the current flowing through the transmitting coil, and other factors. Air has a relatively poor magnetic permeability characteristic of $\mu = 4\pi \times 10^{-7}$ Henry/meter,
15 and the magnetic permeability of the dermal layer separating an internal receiving coil from an external transmitting coil is only slightly better. By comparison, the magnetic permeability characteristic of iron is approximately $\mu = 100$ to 600 Henry/meter. The variation in the magnetic permeability of iron is inversely
20 proportional to the density of the magnetic flux. Thus, transcutaneous electromagnetic power transfer between two coils is relatively inefficient compared to the efficiency that could be achieved if the two coils were coupled by a material such as iron, having a superior magnetic permeability.

Clearly, it is desirable to limit the amount of time required for inductively
25 coupling electrical power to charge an internal battery supply used to energize an implanted device. Similarly, it would be desirable to improve the efficiency with which power is coupled to an implanted device that is directly energized by transcutaneously transferred power. The time required to charge a battery pack is generally proportional to the efficiency of the inductive coupling process. In
30 addition, due to miniaturization of the receiving coil used in certain types of implanted devices, it is very important to optimize the inductive coupling between the external transmitter coil and the receiving coil connected to the internal device, particularly when the device is directly energized. Design changes in the transmitter and receiver coils are likely only to achieve a minimal improvement in
35 the efficiency of the power transfer process. Further enhancements to the efficiency of the process will require a different approach.

Summary of the Invention

The present invention is directed to a method for enhancing transcutaneous energy transfer that is used to provide electrical power to a medical device implanted within a patient's body. Transcutaneous energy transfer employs a transmitting coil that is disposed externally, generally in contact with a patient's skin and positioned directly over or opposite a receiving coil that has been implanted within the patient's body. The external transmitting coil produces a magnetic field that induces a current in the internal receiving coil, which is used to supply energy for the implanted medical device.

The magnetic permeability of tissue is low, so that the coupling between the external transmitting coil and the internal receiving coil is relatively poor. The present invention addresses this problem by improving the coupling between the transmitting and receiving coils. In the invention, a plurality of particles having a characteristic relatively high magnetic permeability are implanted in the patient's body, above the internal receiving coil and under the top surface of the patient's skin. These particles improve the transfer of electromagnetic energy by enhancing the magnetic permeability of the flux path between the transmitting and receiving coils.

Materials such as soft iron, permalloy, mu metal alloy, and supermalloy comprise a core of each of the particles, and the core is coated with a protective biocompatible layer. This layer can be manufactured in various colors to selectively cosmetically mask the particles, minimizing their visibility through the skin, or alternatively, to enhance the visibility of the particles, making it easier to locate the internal receiving coil that lies under the particles. Each particle has a size within the range from about 50 micrometers to about one millimeter.

A further aspect of the present invention is directed to a method for implanting a plurality of such particles at a site within the patient's body. Preferably, the particles are added to a liquid so that they are suspended, forming a mixture. The mixture is then injected into the patient's body, using a hypodermic needle or an air injection gun. Alternatively, a plurality of small incisions may be made in the patient's skin and the particles implanted in the incisions.

Brief Description of the Drawing Figures

The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated as the same becomes better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:

FIGURE 1 is a cross-sectional view of one of the particles of the present invention, showing a biocompatible coating around a core;

FIGURE 2 is a side section view of skin containing implanted particles having a relatively high magnetic permeability in accord with the present invention and illustrating a transmitter coil and a receiving coil that couple power
5 transcutaneously through a path comprising the particles;

FIGURE 3 is a side sectional view of skin showing a hypodermic needle inserted into the skin and showing the deposition of the particles in the dermis as the needle is withdrawn;

10 FIGURE 4 is a side sectional view of the skin showing the needle further withdrawn (compare to FIGURE 3) as the particles are injected;

FIGURE 5 is a side sectional view of the skin with a needle positioned above the top surface of the skin and showing the particles deposited within the skin;

15 FIGURE 6 is a side sectional view of the skin with a medical air injection nozzle positioned against the top surface of the skin and showing the result of having uniformly deposited magnetically permeable particles within the skin by air injection;

20 FIGURE 7 is a side sectional view of the skin, showing a heavy deposit of particles within the skin;

FIGURE 8 is a side sectional view of the skin, showing a light deposit of the particles within the skin; and

FIGURE 9 is a side sectional view of the skin, showing a columnar deposit of the particles within the skin.

25 **Description of the Preferred Embodiment**

A first embodiment of a technique to improve transcutaneous energy transfer to a medical device (not shown) that has been implanted within a patient's body is illustrated in FIGURE 2. The human body is protected by a layer of skin 100, generally comprising a top layer or epidermis 102, and a bottom layer or
30 dermis 104. The skin is part of a very complex group of organs collectively referred to as the integumentary system. Also included within this system are hair follicles 114, sweat glands 108, and capillary blood vessels 110. The skin borders an internal layer of subcutaneous tissue or hypodermis 106. Hypodermis 106 anchors skin 100 to the underlying structure of the body, yet allows the skin to
35 move relative to the body.

Although the magnetic permeability of the integumentary system is slightly better than air, it is still relatively poor, which substantially limits the efficiency with which electromagnetic power can be transferred transcutaneously. It will be recalled from the discussion in the Background of the Invention that
5 transcutaneous energy transfer provides means for coupling power from an external source to an internally disposed medical device that has been surgically implanted within the body of a patient. The present invention greatly improves the efficiency with which power is transmitted transcutaneously for this purpose.

As illustrated in FIGURE 2, an external transmitting coil 200 is illustrated
10 in contact with epidermis 102, generally opposite a receiving coil 300, which has been surgically or endoscopically implanted below hypodermis 106. Transmitting coil 200 comprises a winding 204, a core 202, and wire leads 206. Wire leads 206 are connected to an external power supply that provides an AC voltage, forcing a substantial current to flow through winding 204, so that a corresponding AC
15 magnetic field is produced by transmitting coil 200. It will be apparent that winding 204 could also be energized with a pulsating DC voltage.

Receiving coil 300 comprises a winding 304, a core 302, and wire leads 306. Wire leads 306 are used to transfer current induced in winding 304 to the remotely disposed medical device that is implanted within the patient's body.
20 The current induced in winding 304 can be used directly to power the device or can be rectified and applied to charging a battery that normally provides power to the implanted device. Details of the medical device circuitry are not illustrated in the drawings nor described in this disclosure, since such details are irrelevant to the present invention.

25 The transmitting coil has a winding wrapped around a generally U-shaped core. The receiving coil similarly includes a winding wrapped around a generally U-shaped core. The windings are wrapped around each core in concentric layers (not separately shown). The magnetic flux density within core 202 of transmitting coil 200 is dependent upon the magnetic permeability characteristics of
30 transmitting core 202, the number of turns of conductor comprising winding 204, and the magnitude of the current flowing through winding 204. The materials comprising core 202 and core 302 are selected because of their characteristic high magnetic permeability to optimize the magnetic flux density within the cores. Core 202 directs and focuses the magnetic flux from winding 204 out through
35 pole faces 203, which are disposed at opposite ends of the core. On receiving coil 300, opposite ends of core 302 comprise pole faces 303 that receive the

magnetic flux produced by transmitting coil 200 and direct the flux through the core of receiving coil 300. The magnetic flux within core 302 causes an electrical current to be induced in winding 304 that is proportional to the intensity of the magnetic flux within the core, and to the number of turns of the conductor comprising winding 304. However, the amount of power transferred to receiving coil 300 to produce the flux within core 302 is directly proportional to the magnetic permeability of the material *between* pole faces 203 and 303.

Power transfer between the transmitting coil and the receiving coil can be improved in two ways. First, the magnitude of the magnetic flux produced by the transmitting coil can be increased, e.g., by increasing the current flowing in the windings of the transmitting coil. However, a higher current requires physically larger windings, i.e., more turns of the conductor comprising the winding, and may require a larger gauge conductor to safely carry the higher current. There is a practical limit to the size of the transmitting coil used for this purpose. A second way to improve power transfer is to increase flux density coupling between the facing pole faces of the transmitting and receiving coils. The flux density can be increased by increasing the magnetic permeability of the material comprising the physical barrier separating the pole faces of the transmitting coil from the pole faces of the receiving coil. The second technique increases the efficiency of power transfer without requiring any modification of the transmitting and receiving coils or any changes in the power supply or current that energizes transmitting coil 200. The present invention is thus directed to increasing the magnetic permeability of the tissue separating transmitting coil 200 and receiving coil 300 to improve the efficiency with which electromagnetic energy is transferred between the two coils.

To improve the magnetic permeability of skin or other tissue disposed between the transmitting and receiving coils, magnetically permeable particles 120 are implanted within the tissue of a patient's body at that site so that the particles lie between the pole faces of the two coils. To facilitate their implantation at the site, particles 120 are preferably added to a saline solution or other biocompatible liquid to form a mixture in which the particles are at least initially suspended. The mixture is then drawn into a delivery device and the delivery device is positioned on the top surface of skin 100, at the site overlying receiving coil 300. Using the delivery device, the mixture is forced into dermis 104 at the site. These steps are repeated as necessary to achieve a desired

density of particles 120 beneath epidermis 102, and create a generally uniform distribution of the particles, at least overlying pole faces 303 of receiving coil 300.

In FIGURE 3, a hypodermic needle 150 is illustrated as the delivery device used to implant particles 120 at the site. Hypodermic needle 150 is shown after it has been inserted through epidermis 102 and into dermis 104. The tip of the needle rests just above hypodermis 106 and the particles are being injected through the needle as it is withdrawn from the dermis. In FIGURE 4, hypodermic needle 150 is shown partially withdrawn from dermis 104, leaving behind a columnar deposit of particles 120. These particles are deposited within the column at a substantially uniform density. The implanted particles have a characteristic magnetic permeability that is substantially greater than skin and thus greatly improves the efficiency of transcutaneous electromagnetic power transfer between the transmitting coil and receiving coil.

As shown in FIGURE 1, each particle 120 comprises a core 121 of a material such as soft iron, permalloy, mu metal alloy, or supermalloy having a characteristic high magnetic permeability. A coating 123 of a biocompatible material such as one of the polyurethane or TEFLON™ compounds typically used for coating medical implants is applied to the particle core. Particles 120 are substantially spherical, and can have a diameter from about 50 micrometers to about 1 millimeter. Since epidermis 102 is relatively translucent, particles 120 may discolor the skin at the site of their implantation, possibly causing it to appear a mottled gray color. However, by coloring coating 123 various appropriate flesh colors, particles 120 may be made to cosmetically blend with the skin of the patient. This option is further discussed below.

Referring now to FIGURE 5, hypodermic needle 150 is illustrated positioned above epidermis 102 after it has been used to implant multiple columnar deposits of particles 120 within dermis 104. The resulting multiple columnar deposits of particles implanted beneath epidermis 102 are generally analogous to the dye pigment deposits introduced into the dermis when creating a tattoo. A tattoo artist employs a needle to inject multiple colored pigment clusters, having diameters of approximately 140 to 180 micrometers, beneath the top surface of the skin. The deposits of dye pigment define the tattoo. Similarly, in the present invention, a particular area of skin located above a receiving coil is injected with multiple deposits of particles 120, and the particles are generally analogous to the colored pigment clusters of a tattoo. However, epidermis 102 is relatively translucent and a patient treated with the present invention may prefer

that the introduction of particles 120 not change the appearance of the skin. In other cases, it may be preferable that the implanted particles be clearly visible to facilitate accurately positioning transmitting coil 200 against epidermis 102, immediately opposite receiving coil 300. Thus, the color of coating 123 on particles 120 may be selected to either enhance or reduce the extent to which the particles are visible through epidermis 102.

An alternative method for implanting particles 120 is illustrated in FIGURE 6. In this Figure, a medical air injection nozzle 160 having an injection channel 162 is shown positioned above a columnar deposit of particles 120 that have been injected into the dermis using the device. The air injection nozzle employs pressurized air to force a plurality of particles 120 through epidermis 102, producing a columnar deposit of particles 120 within dermis 104. One advantage of the air injection nozzle method for implanting the particles is the capacity of this device to deliver a generally uniform density of implanted particles with each injection. In contrast, the columnar deposit density can vary between columns when a hypodermic needle is employed to implant particles 120. The density of the particles injected using a hypodermic needle is dependent upon the pressure applied by a particular individual against a plunger of the syringe (not shown) and the rate at which the needle is withdrawn as the injection is delivered, both of which can vary.

Particles 120 can be implanted within tissue in various selected densities. For example, referring to FIGURE 7, a uniform high density deposit of particles 120 is shown implanted beneath epidermis 102. In FIGURE 8, a uniform light density deposit of particles 120 is shown, and in FIGURE 9, multiple columnar high density deposits of particles 120 are illustrated. Typically, a medical practitioner would select an appropriate density deposit of particles 120 for use with a specific patient, to provide a required magnetic flux density for the transfer of electromagnetic energy from transmitting coil 200 to receiving coil 300. Various parameters that may determine the density of the particles used with a specific patient include the power requirement of the medical device being energized, the thickness of skin 100 at the site selected, the size of the implanted receiver coil, the electrical current supplied to the transmitting coil, the size of the transmitting coil, (i.e., the number of turns of conductor used for winding 204), and the distribution of the flux pattern.

As an alternative to injecting the particles using a needle or air injection nozzle, as described above, it is also contemplated that a plurality of small

incisions can be made through epidermis 102 and into dermis 104 at the site overlying receiving coil 300. The particles can then be implanted within the pockets formed by the incisions, using a small catheter or other appropriate tools, leaving a columnar deposit of the particles at each small incision.

5 It is also contemplated that the present invention can be employed in connection with the implantation of particles within bones and/or tissue at other sites within the body to improve the magnetic permeability, which couples a transmitting coil and receiving coil and the power transferred between the two coils. To reach implantation sites deep within a patient's body, a longer
10 hypodermic needle could be employed or the site could be surgically exposed to facilitate the injection of the particles using an air injection nozzle or needle.

 Although the present invention has been described in connection with several preferred forms of practicing it, those of ordinary skill in the art will understand that many other modifications can be made thereto within the scope of
15 the claims that follow. Accordingly, it is not intended that the scope of the invention in any way be limited by the above description, but instead be determined entirely by reference to the claims that follow.

The invention in which an exclusive right is claimed is defined by the following:

1. A method for enhancing transcutaneous energy transfer within a body, comprising the steps of:

(a) providing a plurality of particles comprising a material having a characteristic magnetic permeability substantially greater than that of tissue in the body; and

(b) implanting the plurality of particles at a site within the tissue of the body so that the plurality of particles are dispersed in a spaced-apart array, said plurality of particles comprising an enhanced flux path for transferring electromagnetic energy through the tissue at said site.

2. The method of Claim 1, further comprising the step of applying a biocompatible coating to each of the plurality of particles.

3. The method of Claim 2, wherein the step of coating includes the step of coloring the coating to either make the coating more or less visible relative to a patient's skin color.

4. The method of Claim 1, wherein the step of implanting includes the step of mixing the plurality of particles into a liquid to form a mixture.

5. The method of Claim 4, further comprising the step of injecting the mixture into the tissue at said site.

6. The method of Claim 4, further comprising the step of injecting the mixture into the tissue at said site using an air gun.

7. The method of Claim 4, further comprising the step of injecting the mixture into the tissue at said site using a needle.

8. The method of Claim 1, further comprising the step of making a plurality of incisions in the tissue adjacent to the site and implanting the plurality of particles in the plurality of incisions.

9. The method of Claim 1, wherein each of the plurality of particles has a size within the range from about 50 micrometers to about one millimeter.

10. The method of Claim 1, wherein the plurality of particles are implanted within the tissue in a plurality of spaced-apart columns.

11. Apparatus for enhancing transcutaneous energy transfer within a body, comprising:

(a) a plurality of particles comprising a material having a characteristic magnetic permeability substantially greater than that of tissue in the body; and

(b) means for implanting the plurality of particles at a site within the tissue of the body so that the plurality of particles are dispersed in a spaced-apart array, said plurality of particles comprising an enhanced flux path for transferring electromagnetic energy through the tissue at said site.

12. The apparatus of Claim 11, wherein the plurality of particles are each coated with a layer of a biocompatible material.

13. The apparatus of Claim 12, wherein the layer of the biocompatible material is selectively colored to make the particles either more or less visible relative to a patient's skin.

14. The apparatus of Claim 11, wherein the plurality of particles are mixed into a liquid to form a mixture prior to being implanted in the tissue at the site.

15. The apparatus of Claim 14, wherein the means for implanting the plurality of particles comprise an air gun that is employed to inject the plurality of particles within the mixture into the tissue at the site.

16. The apparatus of Claim 14, wherein the means for implanting the plurality of particles comprise a needle that is employed to inject the plurality of particles within the mixture into the tissue at the site.

17. The apparatus of Claim 11, wherein each of the plurality of particles has a size within the range from about 50 micrometers to about one millimeter.

18. The apparatus of Claim 11, wherein the plurality of particles are implanted in generally uniform density deposits, having a density selected to achieve a required magnetic permeability.

19. The apparatus of Claim 11, wherein the material comprising the plurality of particles is selected from the group consisting of soft iron, permalloy, mu metal alloy, and supermalloy.

AMENDED CLAIMS

[received by the International Bureau on 1 September 1997 (01.09.97); original claims 1-3, 5-7 and 10-19 amended; new claims 20-22 added; remaining claims unchanged (3 pages)]

The invention in which an exclusive right is claimed is defined by the following:

1. A method for enhancing transcutaneous energy transfer from an external source to a receiver implanted within a body to energize a medical device disposed within the body, comprising the steps of:

(a) providing a plurality of particles comprising a material having a characteristic magnetic permeability substantially greater than that of tissue in the body; and

(b) implanting the plurality of particles at a site within the tissue of the body so that the plurality of particles are dispersed in a spaced-apart array, said plurality of particles comprising an enhanced flux path between the external source and the receiver for transferring electromagnetic energy through the tissue at said site and thereby adapted to energize the medical device.

2. The method of Claim 1, wherein each of the plurality of particles further comprises a biocompatible coating.

3. The method of Claim 2, wherein the biocompatible coating is colored to either make the biocompatible coating more or less visible relative to a patient's skin color.

4. The method of Claim 1, wherein the step of implanting includes the step of mixing the plurality of particles into a liquid to form a mixture.

5. The method of Claim 4, wherein the step of implanting further comprises the step of injecting the mixture into the tissue at said site.

6. The method of Claim 4, wherein the step of implanting further comprises the step of injecting the mixture into the tissue at said site using an air gun.

7. The method of Claim 4, wherein the step of implanting further comprises the step of injecting the mixture into the tissue at said site using a needle.

8. The method of Claim 1, further comprising the step of making a plurality of incisions in the tissue adjacent to the site and implanting the plurality of particles in the plurality of incisions.

9. The method of Claim 1, wherein each of the plurality of particles has a size within the range from about 50 micrometers to about one millimeter.

10. The method of Claim 1, wherein the step of implanting further comprises the step of disposing the plurality of particles within the tissue in a plurality of spaced-apart columns.

11. A kit having components capable of being used together for enhancing transcutaneous energy transfer between an external energy source and a receiver implanted within a body to energize a medical device disposed within the body, comprising:

(a) a plurality of particles comprising a material having a characteristic magnetic permeability substantially greater than that of tissue in the body and adapted to be implanted within the body; and

(b) means adapted for implanting the plurality of particles at a site within the tissue of the body so that the plurality of particles are dispersed in a spaced-apart array, said plurality of particles, when implanted by said means, comprising an enhanced flux path for transferring electromagnetic energy through the tissue at said site to energize the medical device.

12. The kit of Claim 11, wherein the plurality of particles are each coated with a layer of a biocompatible material.

13. The kit of Claim 12, wherein the layer of the biocompatible material is selectively colored to make the particles either more or less visible relative to a patient's skin.

14. The kit of Claim 11, wherein the plurality of particles are adapted to be mixed into a liquid to form a mixture prior to being implanted in the tissue at the site.

15. The kit of Claim 14, wherein the means for implanting the plurality of particles comprise an air gun that is adapted to inject the plurality of particles within the mixture into the tissue at the site.

16. The kit of Claim 14, wherein the means for implanting the plurality of particles comprise a needle that is adapted to inject the plurality of particles within the mixture into the tissue at the site.

17. The kit of Claim 11, wherein each of the plurality of particles has a size within the range from about 50 micrometers to about one millimeter.

18. The apparatus of Claim 11, wherein the means for implanting and the plurality of particles are adapted to implant the plurality of particles in generally uniform density deposits, having a density selected to achieve a required magnetic permeability.

19. The kit of Claim 11, wherein the material comprising the plurality of particles is selected from the group consisting of soft iron, permalloy, mu metal alloy, and supermalloy.

20. A method for enhancing transcutaneous energy transfer within a body, comprising the steps of:

(a) providing a plurality of particles comprising a material having a characteristic magnetic permeability substantially greater than that of tissue in the body, said plurality of particles each including a biocompatible coating; and

(b) implanting the plurality of particles at a site within the tissue of the body so that the plurality of particles are dispersed in a spaced-apart array, said plurality of particles comprising an enhanced flux path for transferring electromagnetic energy through the tissue at said site.

21. A method for enhancing transcutaneous energy transfer within a body, comprising the steps of:

(a) providing a plurality of particles comprising a material having a characteristic magnetic permeability substantially greater than that of tissue in the body, each of said plurality of particles including a biocompatible coating that is colored to either make the biocompatible coating more or less visible relative to a patient's skin color; and



(b) implanting the plurality of particles at a site within the tissue of the body so that the plurality of particles are dispersed in a spaced-apart array, said plurality of particles comprising an enhanced flux path for transferring electromagnetic energy through the tissue at said site.



22. A method for enhancing transcutaneous energy transfer within a body, comprising the steps of:

(a) providing a plurality of particles comprising a material having a characteristic magnetic permeability substantially greater than that of tissue in the body; and



(b) implanting the plurality of particles at a site within the tissue of the body so that the plurality of particles are dispersed in a spaced-apart array comprising a plurality of spaced-apart columns, said plurality of spaced-apart columns comprising an enhanced flux path for transferring electromagnetic energy through the tissue at said site.

1/4





3/4



4/4




Fig. 7




Fig. 8




Fig. 9

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/11051

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A61M 37/00 US CL :600/12 According to International Patent Classification (IPC) or to both national classification and IPC														
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 128/897-899; 600/3, 12, 13; 607/33, 34, 61 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)														
C. DOCUMENTS CONSIDERED TO BE RELEVANT														
<table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:10%;">Category*</th> <th style="width:60%;">Citation of document, with indication, where appropriate, of the relevant passages</th> <th style="width:30%;">Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td style="text-align:center; vertical-align:top;">X --- Y</td> <td style="vertical-align:top;">US 5,067,952 A (GUDOV et al) 26 November 1991, entire document.</td> <td style="vertical-align:top;">1, 4, 5, 9, 11, 14, 17 ----- 6-8, 15, 16</td> </tr> <tr> <td style="text-align:center; vertical-align:top;">X --- Y</td> <td style="vertical-align:top;">US 4,829,984 A (GORDON) 16 May 1989, entire document.</td> <td style="vertical-align:top;">1, 4, 5, 11, 14, 18, 19 ----- 6-8, 15, 16</td> </tr> <tr> <td style="text-align:center; vertical-align:top;">X --- Y</td> <td style="vertical-align:top;">US 5,262,176 A (PALMACCI et al) 16 November 1993, entire document.</td> <td style="vertical-align:top;">11, 12, 14, 19 ----- 13</td> </tr> </tbody> </table>	Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X --- Y	US 5,067,952 A (GUDOV et al) 26 November 1991, entire document.	1, 4, 5, 9, 11, 14, 17 ----- 6-8, 15, 16	X --- Y	US 4,829,984 A (GORDON) 16 May 1989, entire document.	1, 4, 5, 11, 14, 18, 19 ----- 6-8, 15, 16	X --- Y	US 5,262,176 A (PALMACCI et al) 16 November 1993, entire document.	11, 12, 14, 19 ----- 13	<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X --- Y	US 5,067,952 A (GUDOV et al) 26 November 1991, entire document.	1, 4, 5, 9, 11, 14, 17 ----- 6-8, 15, 16												
X --- Y	US 4,829,984 A (GORDON) 16 May 1989, entire document.	1, 4, 5, 11, 14, 18, 19 ----- 6-8, 15, 16												
X --- Y	US 5,262,176 A (PALMACCI et al) 16 November 1993, entire document.	11, 12, 14, 19 ----- 13												
<table style="width:100%; border-collapse: collapse;"> <tr> <td style="width:50%; border-right: 1px solid black; padding: 5px;"> * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width:50%; padding: 5px;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family </td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family										
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family													
Date of the actual completion of the international search 04 AUGUST 1997	Date of mailing of the international search report 19 AUG 1997													
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer <i>Diane Smith for</i> GE RGE ROBERT EVANISKO Telephone No. (703) 308-2612													